Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Carcinoma, Hepatocellular × 4-toluenesulfonamide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Solid Tumor 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1

Interventions

Sorafenib 70 pembrolizumab 34 Bevacizumab 29 lenvatinib 28 Nivolumab 27 atezolizumab 20 durvalumab 16 Ipilimumab 11 Oxaliplatin 9 tremelimumab 8 Doxorubicin 8 tislelizumab 7 Injections 7 Capecitabine 7 budigalimab 6 Ramucirumab 6 Fluorouracil 6 sintilimab 5 regorafenib 5 cabozantinib 5 brivanib 5 Everolimus 5 ADI PEG20 5 Sunitinib 4 Gemcitabine 4 E-7386 4 Cyclophosphamide 4 Cisplatin 4 ARQ 197 4 toripalimab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03447951 2023-09-13

OASES

Gongwin Biopharm Co., Ltd.

Phase 2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡